Drive Cost-Efficiencies with Real-World Evidence (RWE)

April 26, 2016
Pharmaceutical Companies today need post-approval data to demonstrate product value in an environment where costs are more tightly controlled than ever before. PAREXEL Access Real World Evidence Ecosystem helps clients plan at a portfolio level, providing greater strategic advantage and the ability to identify greatest cost-efficiency for evidence generation. Joshua Schultz, Corporate VP and Head of PAREXEL Access, explains that through our Real-World Evidence Ecosystem, we drive average cost savings of around 20% by combining multiple late-stage studies. PAREXEL Access has an integrated market access consultancy, supporting more than 200 HTA submissions, in 12 countries, and over 200 economic modeling programs.
Previous Video
Drive Efficiency by Bridging Clinical and Commercial Functions
Drive Efficiency by Bridging Clinical and Commercial Functions

The evolving pharmaceutical environment is requiring pharmaceutical companies to bridge the gap between cli...

Next Video
Maximize your ROI with Real-World Evidence (RWE)
Maximize your ROI with Real-World Evidence (RWE)

Many Pharmaceutical companies need to generate efficiencies in developing and commercializing products. PAR...